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Fanconi anemia (FA) is a genetically heterogeneous rare autosomal recessive disorder characterized by congenital
malformations, hematological problems and predisposition to malignancies. The genes that have been found to be
mutated in FA patients are called FANC. To date 16 distinct FANC genes have been reported. Among these, mutations
in FANCA are the most frequent among FA patients worldwide which account for 60- 65%. In this study, a nine years
old male child was brought to our hospital one year ago for opinion and advice. He was the third child born to
consanguineous parents. The mutation analyses were performed for proband, parents, elder sibling and the relatives
[maternal aunt and maternal aunt’s son (cousin)]. Molecular genetic testing [targeted next-generation sequencing
(MiSeq, Illumina method)] was performed by mutation analysis in 15 genes involved. Entire coding exons and their
flanking regions of the genes were analysed. Sanger sequencing [(ABI 3730 analyzer by Applied Biosystems)] was
performed using primers specific for 43 coding exons of the FANCA gene. A novel splice site mutation, c.3066 + 1G > T,
(IVS31 + 1G > T), homozygote was detected by sequencing in the patient. The above sequence variant was identified in
heterozygous state in his parents. Further, the above sequence variant was not identified in other family members
(elder sibling, maternal aunt and cousin). It is concluded that genetic study should be done if possible in all the cases
of suspected FA, including siblings, parents and close blood relatives. It will help us to plan appropriate treatment and
also to select suitable donor for hematopoietic stem cell transplantation and to plan for genetic counseling. In addition
to the case report, the main focus of this manuscript was to review literature on role of FANCA gene in FA since large
number of FANCA mutations and polymorphisms have been identified.
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Fanconi anemia (FA) is a genetically heterogeneous rare
autosomal recessive disorder characterized by congenital
malformations, hematological problems and predispos-
ition to malignancies [1]. The genes that have been
found to be mutated in FA patients are called FANC. To
date 16 distinct FANC genes (FANCA, FANCB, FANCC,
FANCD1 (also known as BRCA2), FANCD2, FANCE,
FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM,
FANCN, FANCO, FANCP, and FANCQ) have been re-
ported [2-5]. Among these, mutations in FANCA are the* Correspondence: pjohnsolomon@yahoo.co.in; godfredmenezes@gmail.com
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unless otherwise stated.most frequent among FA patients worldwide which ac-
count for 60- 65% [2,6-8]. As large number of FANCA
mutations and polymorphisms have been identified, the
FANCA is considered as a hyper-mutable gene [2,6,7,9-12].
In this study targeted next-generation sequencing (MiSeq,
Illumina method) was performed by mutation analysis
in 15 genes- BRCA2, BRIP1, FANCA, FANCB, FANCC,
FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL,
FANCM, PALB2 (FANCN), RAD51C (FANCO), and
SLX4 (FANCP), then novel non-synonymous variants
were confirmed by Sanger sequencing (ABI 3730
analyzer by Applied Biosystems). Entire coding exons
and their flanking regions of the genes were analysed.
Sanger sequencing was performed using primers spe-
cific for 43 coding exons of the FANCA gene. A novel
splice site mutation, c.3066 + 1G > T, (IVS31 + 1G > T),
homozygote was detected by sequencing in the patient.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gous state in his parents. Further, the above sequence
variant was not identified in other family members
(elder sibling, maternal aunt and cousin). In addition to
the case report, the main focus of this manuscript was
to review literature on role of FANCA gene in FA since




A nine years old male child was brought to us one year
ago for opinion and advice. He was already seen in many
other tertiary care centres and was diagnosed to have
Fanconi Anemia (FA) at 8 years of age. The subject’s
cytogenetic report was positive for mitomycin-C (MMC)
induced chromosomal aberrations. Since then he has
been getting blood transfusion, now almost once in a
month. He is the third child born to consanguineous
parents. The first child was a male and was diagnosed to
have FA at 8 years of age. He was on anabolic steroids
and periodic blood transfusions but died at 10 years of
age due to intracranial bleed. The second child is also a
male and is now 20 years old and normal.
The index case was born at term by Lower Segment
Caesarean Section (LSCS) and was small for gestational
age. The birth weight was 2.3 Kg. He used to get recur-
rent respiratory infections and feeding problems. The
mother noticed that his heart was beating abnormally
and hence an Echocardiogram (ECHO) was done at five
months of age and was found to have Patent Ductus
Arteriosus (PDA). It was ligated. After 1 year of age he
had recurrent Urinary Tract Infection (UTI). Investiga-
tions revealed that he had chronic atrophic pyeloneph-
ritis of right kidney due to Vesico Ureteric Reflux.
Micturating Cystourethrography (MCU) showed Grade
IV reflux on right side and Grade III reflux on left side.
Hence Sting procedure was done. Subsequent scan done
showed that the left kidney was functioning normally. At
3 years of age he developed bruising on right thigh. In-









FANCF NG_007425.1, NM_022725.3FA. Since then he has required platelets and packed red
cells, now almost every month.
On examination, his weight was 30 Kg (Expected – 29
Kg), Head circumference – 51 cm (Expected – 53 cm),
Height 133 cm (Expected – 131 cm), Upper segment
was 59 cm; Lower segment was 74 cm. External genitalia
was normal. Patient had pallor, left sided squint, high
arched palate, short neck, mild gynecomastia, hyperpig-
mentation of nail beds and palms. The cardiovascular
system (CVS) examination revealed grade 2/6 soft sys-
tolic murmur. Other systems were normal.
We were interested in performing genetic study of the
case which would also help in proper genetic counselling
to the family. After obtaining informed consent from the
family 2 mL ethylene diamine tetra-acetic acid (EDTA)
blood was collected from proband, parents, elder sibling
and the relatives [maternal aunt and maternal aunt’s son
(cousin)] for mutation analysis. The extracted DNA was
sent to the Department of Laboratory Medicine, Seoul
National University Hospital, Seoul, Korea for mutation
analysis under collaboration study.
DNA extraction for molecular genetic testing
DNA extraction
After obtaining informed consent, 2 mL ethylene diamine
tetra-acetic acid (EDTA) blood samples were collected
from proband, parents, elder sibling and the relatives
[maternal aunt and maternal aunt’s son (cousin)]. The
genomic DNA was isolated from white blood cells by
Phenol: Chloroform: Isoamylalcohol method [13].
Molecular genetic testing
The targeted next-generation sequencing (MiSeq, Illu-
mina method) was performed by mutation analysis using
a multigene panel consisted of 15 genes- BRCA2, BRIP1,
FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF,
FANCG, FANCI, FANCL, FANCM, PALB2 (FANCN),
RAD51C (FANCO), and SLX4 (FANCP) [14]. Entire cod-
ing exons and their flanking regions of the genes were
analysed. The reference sequences have been mentioned
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(Illumina). Among the variants detected, all previously
reported mutations and probable pathogenic variants
including novel non-synonymous ones were confirmed
by Sanger sequencing, as well as all low-coverage re-
gions with coverage depth under 10X. Sanger sequen-
cing was performed using primers specific for 43
coding exons of the FANCA gene. The amplified prod-
ucts were sequenced on an ABI 3730 analyzer (Ap-
plied Biosystems, Foster City, CA, USA) using a
BigDye Terminator v3.1 Cycle sequencing kit (Applied
Biosystems). The variant were queried against the
public version of the Human Gene Mutation Database
(HGMD, http://www.hgmd.cf.ac.uk/). For nucleotide
numbering Nucleotide c.1 was the “A” of the initiation
codon and for Amino acid numbering p.1 was the ini-
tiation codon, ATG.Results
Analysis of FANCA mutation
A novel splice site mutation, c.3066 + 1G > T, (IVS31 +
1G > T), homozygote was detected by Sanger sequencing
(Reference cDNA sequence: NM_000135.2) (Figure 1).
The above sequence variant was identified in heterozy-
gous state in his parents. Further, the above sequence
variant was not identified in other family members (elder
sibling, maternal aunt and cousin).
The variant found in our study is submitted to ClinVar.
It is a freely accessible, public archive of reports of the re-
lationships among human variations and phenotypes
hosted by the National Center for Biotechnology Informa-
tion (NCBI) and funded by intramural National Institutes
of Health (NIH) funding. The variant submission acces-
sion number is SCV000189618 (http://www.ncbi.nlm.nih.
gov/clinvar/variation/156400/).Figure 1 FANCA mutation- A novel splice site mutation, c.3066+1G>T, dete
parents of proband, shown as electropherograms (Reference cDNA sequenDiscussion
Fanconi anemia is a rare hereditary disorder and charac-
terized by bone marrow failure, chromosome breakage
and development of cancer. We report a case of FA with
classical presentation. The genetic investigation is a
rapid method to identify deletions and duplications, en-
abling faster identification of mutations in FA. A large
spectrum of mutations has been reported in the FANCA
gene, including microdeletions, large deletions, microin-
sertions and point mutations [8-10,15].
In our case, molecular genetic testing by mutation
analysis in 15 FANC genes, exhibited a novel and homo-
zygous splice site mutation, c.3066 + 1G > T, (IVS31 +
1G > T) in FANCA and parents were found to be hetero-
zygous for the same mutation, confirming the diagnosis
of FA. However, since defects in the FANCA gene are re-
ported in high frequency of FA patients and large dele-
tions are the most common mutations in the gene,
molecular genetic testing by mutation analysis has been
found to be a very useful technique for the rapid detec-
tion of genetic changes in FA. Identification of the muta-
tion expands the mutational spectrum of FA, facilitates
prenatal diagnosis and helps in taking decisions on treat-
ment and management of the disease. This is the first
time in the world that this novel mutation is reported in
Fanconi Anemia. The variant submission accession
number is SCV000189618 (http://www.ncbi.nlm.nih.gov/
clinvar/variation/156400/).Review of literature
FA was first described in 1927 by the Swiss Paediatrician
Guido Fanconi. It is a rare genetically inherited auto-
somal disorder characterized by congenital malforma-
tions, progressive pancytopenia, cellular hypersensitivity
to DNA-cross-linking agents, predisposition to acutected in the proband and heterozygous mutation identified in both
ce: NM_000135.2).
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[1]. The developmental and physical abnormalities may
include hyperpigmentation, short stature, malformations
of the thumb and forearms, skeletal anomalies, small
head or eyes, renal problems, hearing defect, heart dis-
ease, gastrointestinal difficulties and hypogonadism. The
incidence of FA is approximately 1 to 5 per million [16].
This condition is more common among the people of
Ashkenazi Jews, with carrier frequency of 1 in 89 [17],
and black South Africans where the carrier frequency is
1 in 83 [18].
The genes that have found to be mutated in FA pa-
tients are called FANC. The genes FANCA, FANCB,
FANCC, FANCD1 (also known as BRCA2), FANCD2,
FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL,
FANCM, FANCN, FANCO, FANCP, and FANCQ have
been identified as responsible for FA [2-5]. All the FANC
genes are autosomal recessive except FANCB, as this
gene is located on the X chromosome [19]. Mutations in
FANCA, FANCC, FANCG and FANCD2 are the most
frequent among FA patients worldwide [20]. Among
these FANCA gene abnormalities account for approxi-
mately 60–70% of FA patients and to date more than
100 types of mutations have been found throughout the
FANCA gene [6-9]. Most of these mutations may lead to
premature termination or intragenic large deletions, pre-
sumably lack protein expression (null-mutations) and al-
tered proteins with a single amino acid substitution [8-10].
FANCA gene
The FANCA gene is located at 16q24.3; more precisely it
is located from base pair 89, 737, 550 to base pair 89,
816, 657 on chromosome 16 and contains 43 exons
spanning 34 to 188 base pairs (Reference sequence
NM_000135.2). It is a relatively large protein consists of
1455 amino acids (163 kDa) [5,21].
FANCA contains a nuclear localization signal (NLS) at
its aminoterminus, a partial leucine zipper like motif be-
tween aminoacids 1069 and 1090 and a five functionalFANCA Gene




Protein size (k Da) 163
Protein domains NLS, NES
Figure 2 FANCA gene details.leucine-rich nuclear export sequences (NESs) [6,22,23]
(Figure 2).
The other names of FANCA are FA, FA1, FAA, FACA,
FANCA_HUMAN, FA_H, FAH, and FANCH. FANCA is
implicated in the complementation group A (FA-A), the
most frequent complementation group accounting for
about 70% of FA cases. Sequencing the FANCA gene
of FA-A patients has demonstrated numerous FANCA
mutations and polymorphisms. Significant diversity of
FANCA mutation in the type and location have been
detected, including insertions, deletions, nonsense, mis-
sense, splicing, frameshift mutations [16-20]. As the
large number of FANCA mutations and polymorphism
have been identified, the FANCA is considered as hyper-
mutable and highly polymorphic gene [2,6,7,9-12].
FANCA protein
FANCA is a multi-subunit complex composed of
FANCA, FANCC, FANCF and FANCG proteins. Fanconi
Anemia genes are functionally related. FANCA, FANCC
and FANCG proteins are components of a nuclear pro-
tein complex. FANCA and FANCC bind each other and
form a FANCA-FANCC complex. FANCG is required
for binding of FANCA-FANCC complex. This complex
is found in abundance in both cytoplasm and nucleus
[24]. In turn FANCA amino terminal nuclear localization
signal is required for FANCG binding and FANCC bind-
ing. The FANCA and FANCG interaction is constitutive
and is not regulated by FANCC or by the products
of other FA genes. Whereas, the binding of FANCC
requires FANCA/FANCG binding and the products of
other Fanconi Anemia genes [25].
FANCA interacts with some of the non FA protein
such as Sorting Nexing protein (SNX5), Brahma-Related
Gene 1 protein (BRG1), IκB Kinase-2 (IKK2), Breast
Cancer 1 (BRCA1) and involves in various functions
(Figure 3).
SNX5 is a FANCA-binding protein. The interaction of
FANCA with the sorting nexin 5 protein (SNX5) may be0 to 89,816,657 Base pairs
, Partial leucine zipper
Protein Binding proteins Function
SNX 5 Intracellular trafficking in transporter
FANCA BRG1 Chromatin remodeling during transcription
IKK2 Cytokine response during cell signaling
BRCA1 DNA damage signaling
Figure 3 FANCA- binding proteins.
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levels increases during overexpression of SNX5 and
traffic with cell surface receptors could be affected by
FANCA [26].
FANCA interacts with BRG1, a major coregulator of
transcription, both in activation and repression, through
chromatin modulation. BRG1 is a subunit of the SWI/
SNF complex; FANCA may take on, this complex to
target genes to enable transcription and DNA repair
mechanism [27]. FANCA transcripts are seen in the
brain, kidney, liver whisker follicles, retina and teeth. In
FANCA expression there is a stage-specific variation,
predominantly within the developing whiskers and the
brain. Some tissues express FANCC, but they are un-
able to show FANCA expression. Thus, FANCA is not
necessarily coupled to that of FANCC [28].
FANCA was also found to associate with the IKK sig-
nalosome through direct interaction with the IKK2 [29].
It remains unclear that, though the phosphorylation
state of several FANCA-associated proteins has been
affected by the kinase activity, the direct phosphorylation
of FANCA by IKK2 has been reported. Additionally,
FANCA binds to the tumor suppressor BRCA1 and
involves in DNA damage signalling.
FANCA functions
The FANCA gene encodes a protein that is involved in a
cell process known as the Fanconi anemia (FA) pathway.
The FA pathway has a specific role in certain type of
DNA damage known as interstrand cross-links (ICLs)
[30-32]. The FANCA protein is a component of FA core
complex. FA core complex activates FANCD2 and
FANCI proteins by a process called monoubiquitination
and forms the FANCD2-FANCI (ID) protein complex,
this complex co-localizes the DNA repair proteins to the
DNA damage site as a result the error can be rectified
and DNA replication can continue [33,34].
FANCA phosphorylation is necessary for the formation
of FA complex and nuclear localization. Despite the fact
that FANCA phosphorylation is required for normal
FANCA function, the specific FANCA phosphorylationsite(s) and the kinase(s) responsible for FANCA phos-
phorylation are unknown [35,36].
The FANCA-FANCG interaction is required for gen-
omic stability. FANCA protects humans from bone mar-
row failure and malignancies by maintaining genomic
integrity. FANCA is primarily localized in the nucleus. It
interacts with cytoplasmic proteins as well as nuclear
proteins, but some data suggest that FANCA has a
distinct cytoplasmic function in addition to a nuclear
function [29,37,38].
To date, little has been learned regarding the regula-
tion of FANCA expression, protein-protein interactions,
and nuclear localization. Multiple FANCA transcripts
have been recognized by Northern blotting technique,
suggesting that FANCA gene may be involved in the
regulation of FANCA expression through the mechan-
ism of alternative splicing [21].FANCA mutations
FANCA is the largest and the most polymorphic FA
gene. FA-A is the most prevalent complementation
group therefore mutation analysis of FA patients with
undefined complementation group is always started in
FANCA gene. Mutation analysis can be performed on
genomic DNA as well as on cDNA [7].
The mutation spectrum in the FANCA gene is very
heterogenous and also it varies from FANCC and
FANCG. More than 100 different mutations that have
been dispersed in the exons and introns of the entire
FANCA gene of the FA patient are described in some
studies [7,8,21]. To the best of our knowledge there are
very few studies with the mutation detection in FA.
The hyper-mutability of FANCA is due to the disper-
sion of large number of repetitive elements throughout
the gene. Repetitive elements include Alu-repeats, short
direct repeats, CpG-islands homonucleotide tracts and
several hotspot-motifs such as CCTG/CAGG. The
FANCA gene possesses all kinds of mutations. The most
frequent mutation includes large deletions which may
span 1-31 exons. In some reports even the deletions
spanning entire FANCA genes have also been described
Solomon et al. Italian Journal of Pediatrics  (2015) 41:38 Page 6 of 8[39]. Some of the Splice site mutations, nonsense and
missense mutations have also been reported. Since the
Patients carrying same mutations and homozygosity are
found rarely, most of the FANCA mutations are called
“private mutations”, except few common mutations [15].
Fanconi anemia reports from India
In a report from India in 2014, molecular analysis of
proband (A 5-year-old girl having hypoplastic anemia)
showed heterotzygous c.1303C > T (rs148473140: R/C)
mutation in FANCA gene. Father was found to be car-
rier for the mutation and the mother was normal [38].
In a conference abstract out of a Indian study by
Arthur et al., 2014 [40] a comprehensive clinical and
molecular analysis in 101 patients with pancytopenia
was performed. A total of 76 patients had characteristic
physical abnormalities of FA, of which perioral hyperpig-
mentation (42%) was the most common in these pa-
tients. The median age at diagnosis was 11 years (range
4-30) and sex ratio between males to females was 3:2.
The chromosome breakage analysis (CBA) was per-
formed on peripheral blood samples at diagnosis. CBA
score greater than the cut off value of 40 was seen in
63% (n = 48/76) of the patients. FANCD2 ubiquitination
investigation of these patients with physical abnormal-
ities in peripheral blood and fibroblasts showed absence
of ubiquitination in 69 (90%) of the patients while the
control group had normal ubiquitination pattern. In
order to further characterize the FA subtypes, fibroblasts
from 20 patients were transduced with lentiviral FANCA
and in 17 (85%) FANCD2 ubiquitination could be restored
suggesting a high frequency of FANCA defects in Indian
population. Mutation screening of FANCA in a subset of
patients showed large deletions in five of which three are
novel (ex 10_37 del,ex 6_14 del and ex 1_4 del). There
was a deletion of two nucleotides resulting in a frameshift
mutation in one patient (c.3760_3761delGA) and a mis-
sense mutation (c.2786A > C) in another. Our data sug-
gests that FANCD2 ubiquitination analysis in conjunction
with CBA is useful for the diagnosis of FA and detection
of mosaicism and the complementation analysis shows
high frequency of FANCA defects in patients with FA in
Indian population [40].
In a proceeding of a conference, Vundini in 2014, [41]
reported molecular study of FA in the Indian population.
FA was screened by CBA using MMC and diepoxybu-
tane (DEB) induction and FANCD2 monoubiquitination
by western blotting to understand gene defects in FA
pathway. The complementation analysis was done by
retroviral transfection. The molecular study was carried
out by Multiplex Ligation-dependent Probe Amplifica-
tion (MLPA) and direct sequencing of FANCA, C, G, E,
F, L, and M genes. The study showed FA-A and E gene
defects in 69% cases and followed by FANCE genedefect. The molecular analysis showed the large dele-
tions in 11 patients and FANCA gene mutations were in
12 FA patients. Out of 12 mutations 5 mutations (c.3678
C > G, p.Ser 1226 X, c.3993G > A p.Leu 1331 Pro, c.1274
C > G p.Glu 425 His, c.2630 C > G p.Ser 877 X) found to
be novel mutations. In the series the single nucleotide
polymorphisms (SNP); Exon9,c.796A > G(p.Thr266Ala),
Exon16,c.1501G > A(p. Gly501Ser), Exon26, c.2426G >
A(p.Gly809Asp), of FANCA gene also observed in 23 pa-
tients, and these polymorphisms in disease association
was reported in FA database. Interesting finding of this
study is the existence of FANCE mutation in Indian
population, and the same was reported rarely in other
places of the world. The study also highlighted the
uncharacterized FA patients, which may be associated
with new genes in Indian population and these patients
should be studied molecularly and genotype-phenotype
correlation need to be established, which assist in better
understanding and supervision of the disease [41].
In a retrospective study carried out in New Delhi, 528
aplastic anemia patient samples were tested for CBA. A
significant increase in chromosomal breakages was seen
in 13.1% patients. The survival data documented for 100
patients suggested 60% mortality [42].
In a case report of FA, the CBA together with
FANCD2 Western blot monoubiquitination assay con-
firmed the diagnosis as FA. MLPA revealed a novel
homozygous large intragenic deletion (exons 8-27 del) in
the FANCA gene in the subject. His siblings and parents
were also analyzed and found to be heterozygous for the
same mutation [43].
In a report in 2010, CBA using DEB induction was
performed in 195 pediatric patients suspected with FA.
CBA showed 33 (17%) patients with classical FA, 9 (4%)
with somatic mosaicism FA, 25 (13%) with FA with high
frequency of chromosomal breakage and without clinical
features, and 128 (66%) with suspected FA but had no
chromosomal breakage and clinical features of FA. CBA
is an important investigation tool for differentiating FA
from idiopathic aplastic anemia [44].
Korgaonkar et al. performed study in 33 clinically di-
agnosed FA patients having aplastic anemia and bleeding
abnormalities. The genetic analysis revealed a signifi-
cantly (P < 0.0001) high frequency (36.4%) of parental
consanguinity in FA patients. CBA revealed spontaneous
chromosome breakage in 63.64% FA patients. Among 33
patients, nine (27.27%) patients developed malignancies
and chromosomal abnormalities were detected in five
(55.5%) patients bone marrow cells including monosomy
5 and 7, trisomy 10, der(1q) and inv(7). Cytogenetic in-
vestigation is important in aplastic anemia to rule out
FA [45].
Varma et al. observed 24.07% (13/54) of FA among bone
marrow failure syndrome (BMFS) patients. Authors found
Solomon et al. Italian Journal of Pediatrics  (2015) 41:38 Page 7 of 8DEB induction a better test than MMC test in screening
FA [46].
In a report of FA in newborn presented with anoph-
thalmia, unilateral radial ray defect, hemivertebrae and
thrombocytopenia, CBA revealed a high frequency of
chromosomal breakage (6.0/metaphase). Chromosomal
analysis of siblings and parents revealed normal karyo-
type. In view of poor long term prognosis, parents re-
fused any further treatment and baby was discharged
against medical advice [47].
Conclusion
It is concluded that genetic study should be done if pos-
sible in all the cases of suspected FA, siblings, parents
and close blood relatives. The screening of the FANCA
gene for mutations supports the clinical diagnosis of FA.
Further, it will help us to plan appropriate treatment and
also to select suitable donor for hematopoietic stem cell
transplantation and to plan for genetic counseling. Fu-
ture studies would clearly advance our understanding of
FANCA regulation and function.
Consent
Written informed consent was obtained from the pa-
tient’s guardian/parent/next of kin for the publication of
this report.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PJ conceived and designed the study and revised the manuscript for
important intellectual content. He will act as the guarantor of the study. PM,
RR, AR collected data and literature and drafted the paper. GA collected
literature, co-ordinated the work and helped in manuscript writing, proof
reading and submitting revised manuscript. AS collected literature and did
proof reading. SJ, MW, SS, DS and SH conducted the laboratory tests and
analysed the sequencing results. All the authors have made substantive
intellectual contributions and have read and approved the final manuscript.
Acknowledgements
The authors thank the co-operating family-members for helping in documenting
the necessary Medical data.
Author details
1Department of Paediatrics, Sree Balaji Medical College and Hospital, Chennai
600 044, India. 2Department of Physiology/Central research laboratory (CRL),
Sree Balaji Medical College and Hospital, Chennai 600 044, India. 3College of
Applied Medical Sciences and Molecular Diagnostics and Personalised
Therapeutics Unit (MDPTU), Ha’il University, Ha’il, Kingdom of Saudi Arabia
(KSA). 4Worked previously as in-charge and scientist in Central Research
Laboratory (CRL), Sree Balaji Medical College and Hospital, Chennai 600 044,
India. 5Department of Laboratory Medicine, Seoul National University
Hospital, Seoul, Korea.
Received: 27 January 2015 Accepted: 22 April 2015
References
1. D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev
Cancer. 2003;3:23–34.
2. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia.
Mutat Res. 2009;668:11–9.3. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the
RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42:406–9.
4. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A.
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43:142–6.
5. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al.
Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause
Fanconi anemia. Am J Hum Genet. 2013;92(5):800–6.
6. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L,
et al. Expression cloning of a cDNA for the major Fanconi anaemia gene,
FAA. Nat Genet. 1996;14:320–3.
7. The Fanconi Anaemia/Breast Cancer Consortium. Positional cloning of the
Fanconi anaemia group A gene. Nat Genet. 1996;14:324–8.
8. Levran O, Erlich T, Magdolena N, Gregory JJ, Batish SD, Verlander PC, et al.
Sequence variation in the Fanconi anemia gene FAA. Proc Natl Acad Sci U
S A. 1997;94:13051–6.
9. Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large
intragenic deletions in the Fanconi anemia group A gene. Am J Hum
Genet. 1999;65:1330–41.
10. Wijker M, Morgan NV, Herterich S, van Berkel CG, Tipping AJ, Gross HJ, et al.
Heterogeneous spectrum of mutations in the Fanconi anemia group A
gene. Eur J Hum Genet. 1999;7:52–9.
11. Ferrer M, Rodriguez JA, Spierings EA, de Winter JP, Giaccone G, Kruyt FA.
Identification of multiple nuclear export sequences in Fanconi anemia
group A protein that contribute to CRM1-dependent nuclear export. Hum
Mol Genet. 2005;14:1271–81.
12. Savino M, Ianzano L, Strippoli P, Ramenghi U, Arslanian A, Bagnara G, et al.
Mutations of the Fanconi anemia group A gene (FAA) in Italian patients.
Am J Hum Genet. 1997;61:1246–53.
13. Ghatak S, Muthukumaran RB, Nachimuthu SK. A Simple Method of Genomic
DNA Extraction from Human Samples for PCR-RFLP Analysis. J Biomol Tech.
2013;24:224–31.
14. Alter BP, Kupfer G. Fanconi anemia. In: Pagon RA, Adam MP, Bird TD, Dolan
CR, Fong CT, Stephens K, editors. GeneReviews™ [Internet]. Seattle (W A):
University of Washington, Seattle; 1993-2013. Available from: http://
www.ncbi.nlm.nih.gov/books/NBK1401/ [updated2013 Feb 07].
15. Centra M, Memeo E, D’Apolito M, Savino M, Ianzano L, Notarangelo A, et al.
Fine exon-intron structure of the Fanconi anemia group A (FAA) gene and
characterization of two genomic deletions. Genomics. 1998;51:463–7.
16. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi
anaemia. Nat Rev Genet. 2001;2:446–57.
17. Verlander PC, Kaporis A, Liu Q, Zhang Q, Seligsohn U, Auerbach AD. Carrier
frequency of the IVS4 + 4 A®T mutation of the Fanconi anemiagene FAC in
the Ashkenazi Jewish population. Blood. 1995;86:4034–8.
18. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, et al. Positional
cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell. 2001;7:241–8.
19. Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, et al. X-linked
inheritance of Fanconi anemia complementation group B. Nat Genet.
2004;36:1219–24.
20. Tachibana A, Kato T, Ejima Y, Yamada T, Shimizu T, Yang L, et al. The FANCA
gene in Japanese Fanconi anemia: reports of eight novel mutations and
analysis of sequence variability. Hum Mutat. 1999;13:237–44.
21. Ianzano L, D’Apolito M, Centra M, Savino M, Levran O, Auerbach AD, et al.
The genomic organization of the Fanconi anemia group A (FAA) gene.
Genomics. 1997;41:309–14.
22. Näf D, Kupfer G, Suliman A, Lambert K, D’Andrea A. Functional activity of
the Fanconi anemia protein FAA requires FAC binding and nuclear
localization. Mol Cell Biol. 1998;18:5952–60.
23. Levran O, Doggett N, Auerbach A. Identification of Alu mediated deletions
in the Fanconi anemia gene FAA. Hum Mutat. 1998;12:145–52.
24. Kupfer GM, Naf D, Suliman A, Pulsipher M, D’Andrea AD. The Fanconi
anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nature
Genet. 1997;17:487–90.
25. Garcia-Higuera I, Kuang Y, Naf D, Wasik J, D’Andrea AD. Fanconi anemia
proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear
complex. Molec Cell Biol. 1999;19:4866–73.
26. Otsuki T, Kajigaya S, Ozawa K, Liu JM. SNX5, a new member of the sorting
nexin family, binds to the Fanconi anemia complementation group A
protein. Biochem Biophys Res Commun. 1999;265:630–5.
27. Otsuki T, Furukawa Y, Ikeda K, Endo H, Yamashita T, Shinohara A, et al.
Fanconi anemia protein, FANCA, associates with BRG1, a component of the
human SWI/SNF complex. Hum Molec Genet. 2001;10:2651–60.
Solomon et al. Italian Journal of Pediatrics  (2015) 41:38 Page 8 of 828. Abu-Issa R, Eichele G, Youssoufian H. Expression of the Fanconi anemia
group A gene (Fanca) during mouse embryogenesis. Blood. 1999;94:818–24.
29. Otsuki T1, Young DB, Sasaki DT, Pando MP, Li J, Manning A, et al. Fanconi
anemia protein complex is a novel target of the IKK signalsome. J Cell
Biochem. 2002;86:613–23.
30. Wang W. Emergence of a DNA-damage response network consisting of
Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735–48.
31. Moldovan GL, D’Andrea AD. How the Fanconi anemia pathway guards the
genome. Annu Rev Genet. 2009;43:223–49.
32. Yuan F, Song L, Qian L, Hu JJ, Zhang Y. Assembling an orchestra: Fanconi
anemia pathway of DNA repair. Front Biosci. 2010;15:1131–49.
33. Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M,
et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat
Cell Biol. 2002;4:913–20.
34. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J,
et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common
pathway. Mol Cell. 2001;7:249–62.
35. Yagasaki H, Adachi D, Oda T, Garcia-Higuera I, Tetteh N, D’Andrea AD, et al.
A cytoplasmic serine protein kinase binds and may regulate the Fanconi
anemia protein FANCA. Blood. 2001;98:3650–7.
36. Yamashita T, Kupfer GM, Naf D, Suliman A, Joenje H, Asano S, et al. The
Fanconi Anemia Pathway Requires Faa Phosphorylation And Faa/Fac
Nuclear Accumulation. Proc Natl Acad Sci U S A. 1998;95(22):13085–90.
37. Meetei AR, Sechi S, Wallisch M, Yang D, Young MK, Joenje H, et al. A
multiprotein nuclear complex connects Fanconi anemia and Bloom
syndrome. Mol Cell Biol. 2003;23:3417–26.
38. Solanki A, Vundinti BR. Prenatal Detection of Fanconi Anemia. Indian
Pediatr. 2014;51:501.
39. Reuter TY, Medhurst AL, Waisfisz Q, Zhi Y, Herterich S, Hoehn H, et al. Yeast
two-hybrid screens imply involvement of Fanconi anemia proteins in
transcription regulation, cell signaling, oxidative metabolism, and cellular
transport. Exp Cell Res. 2003;289:211–21.
40. Arthur NBJ, Ganapule AP, Palani D, Viswabandya A, Mathews V, Abraham A,
Srivastava VM, Srivastava A, George B, Velayudhan SR. Clinical and Molecular
Characterization of Fanconi Anemia: An Indian Perspective. 56th ASH Annual
Meeting and Exposition, Session: 508. Bone marrow failure: Poster II. #2938.
2014. https://ash.confex.com/ash/2014/webprogram/Paper76865.html.
41. Vundinti BR. Chromosomal instability and molecular mutations in multi spectrum
disease of Fanconi anemia. Molecular Cytogenetics. 2014;7 Suppl 1:I47.
42. Chowdhry M, Makroo RN, Srivastava P, Kumar M, Sharma S, Bhadauria P,
et al. Clinicohematological correlation and chromosomal breakage analysis
in suspected Fanconi anemia patients of India. Indian J Med Paediatr Oncol.
2014;35(1):21–5.
43. Shukla P, Rao A, Ghosh K, Vundinti BR. Identification of a novel large
intragenic deletion in a family with Fanconi anemia: first molecular report
from India and review of literature. Gene. 2013;518(2):470–5.
44. Korgaonkar S, Ghosh K, Jijina F, Vundinti BR. Chromosomal breakage study
in children suspected with Fanconi anemia in the Indian population. J
Pediatr Hematol Oncol. 2010;32(8):606–10.
45. Korgaonkar S, Ghosh K, Vundinti BR. Clinical, genetic and cytogenetic study
of Fanconi anemia in an Indian population. Hematology. 2010;15(1):58–62.
46. Varma N, Varma S, Marwaha RK, Malhotra P, Bansal D, Malik K, et al. Multiple
constitutional aetiological factors in bone marrow failure syndrome (BMFS)
patients from north India. Indian J Med Res. 2006;124(1):51–6.
47. Parikh TB, Udani RH, Nanavati RN, Rao B. Fanconi’s anemia in newborn.
Indian Pediatr. 2005;42(3):285–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
